PNET vs adenocarcinoma — the differences that change your plan

Almost everything written about “pancreatic cancer” is about one disease: pancreatic ductal adenocarcinoma. If the word neuroendocrine appears on your pathology report, you are reading about a different one. The two are filed together because they begin in the same organ, and for very little other reason. This page sets out PNET vs adenocarcinoma point by point, so you can work out which of the two your own reports describe and which set of information actually applies to you.

The pancreas does two unrelated jobs in the same piece of tissue. The bulk of it is exocrine: it makes digestive juice, which drains through a branching duct system into the small bowel. Scattered through that tissue are small islands of endocrine cells, the islets, which release insulin, glucagon and other hormones straight into the bloodstream. Adenocarcinoma begins in the duct lining. A pancreatic neuroendocrine tumour — PNET, sometimes written pNET, and called an islet cell tumour in older reports — begins in those hormone-making cells.

That single difference in starting cell carries through everything that follows. The two tumours look different on a contrast scan, are graded on different criteria, are staged on separate systems, are followed with different blood markers, are imaged with different tracers, are treated on different pathways and carry genuinely different outlooks. Pancreatic ductal adenocarcinoma explained covers the common type in full, and pancreatic neuroendocrine tumours explained is the starting point for the neuroendocrine side.

Two honest cautions before the comparison. A PNET is still a cancer, and a minority of them behave aggressively — the label alone is not reassurance. And there is a third thing on this spectrum, poorly differentiated neuroendocrine carcinoma, which arises from neuroendocrine cells but behaves far more like an aggressive adenocarcinoma than like a well-differentiated PNET. If your report says carcinoma rather than tumour, read the checklist below with that in mind.

• Find the diagnosis line on the pathology report. The words that settle it are neuroendocrine tumour or islet cell tumour on one side, and ductal adenocarcinoma on the other. Everything else follows from that line.
• Check whether it says tumour or carcinoma. A well-differentiated neuroendocrine tumour and a poorly differentiated neuroendocrine carcinoma are not the same diagnosis, and the second is treated much closer to the way an aggressive adenocarcinoma is treated.
• Look for a grade and a proliferation index. If the report grades the tumour by how fast its cells are dividing, you are almost certainly reading about neuroendocrine disease. Pancreatic neuroendocrine tumours explained covers what the grade changes.
• Note which blood test the team keeps repeating. A repeated CA 19-9 points to the ductal side. Repeated neuroendocrine markers, or a specific hormone assay, point to the neuroendocrine side.
• Ask whether a somatostatin receptor scan has been requested. A DOTATATE PET is only useful for neuroendocrine disease, so its presence on the plan tells you which pathway the team is on.
• Ask which guideline your plan is being built from. It is a fair question, and the answer should be either the neuroendocrine guideline or the pancreatic adenocarcinoma guideline — not a general one.
• Ask, plainly, which statistics apply to you. Most published pancreatic cancer figures describe the ductal type. If yours is neuroendocrine, those numbers are not your numbers, and nobody should let you go on believing they are.

1. 1

   The exact wording of the report is established

   Before anything is planned, the pathology wording is read carefully — neuroendocrine tumour, neuroendocrine carcinoma or ductal adenocarcinoma. A plan built on the wrong one of those three is the wrong plan.

   In-house at CION
2. 2

   Tissue is obtained where the picture is not yet settled

   A fine-needle sample taken through an endoscope confirms the cell type and, for a neuroendocrine tumour, gives the grade. Very little can be decided properly without it.

   Coordinated with specialist endoscopy partners
3. 3

   Imaging is matched to the tumour type

   Both diseases need a pancreatic-protocol contrast CT. A neuroendocrine tumour may then need a somatostatin receptor scan; an adenocarcinoma needs a careful reading of tumour contact with the vessels behind the gland.

   CT and MRI ordered and reported in-house; receptor PET coordinated with partner nuclear medicine centres
4. 4

   A different first question is asked of each

   For adenocarcinoma the question is resectability. For a neuroendocrine tumour it is grade first, then hormone activity, then whether an operation is warranted at all — and sometimes the honest answer is structured monitoring.

   Tumour board at CION
5. 5

   Systemic treatment is chosen from a different shelf

   Combination chemotherapy carries most of the weight in adenocarcinoma. In neuroendocrine disease the options begin with somatostatin-analogue-class hormone control and targeted oral therapy, with chemotherapy reserved for higher-grade tumours.

   In-house at CION
6. 6

   Review points are written down in advance

   Whichever pathway you are on, the reassessment dates and the scan intervals are agreed at the start, so that nobody is left waiting to see who calls first.

   Free 45-minute consultation

Both pathways are delivered by more than one team, and it is better to know that at the start than to discover it with an invoice. Your first consultation with us is free and lasts 45 minutes. It is a genuine review of your reports by a medical oncologist, not a booking appointment.

Delivered in-house at CION, across 35+ centres in Telangana and Andhra Pradesh: the systemic treatment of both diseases — chemotherapy before or after surgery and in advanced disease, PARP-class maintenance where a BRCA mutation is found, immunotherapy where the tumour is mismatch-repair deficient, and for neuroendocrine disease somatostatin-analogue-class hormone control together with mTOR-inhibitor and TKI-class oral therapy. Also radiation, chemoradiation and SBRT; the ordering and reporting of pancreatic-protocol CT, MRI and MRCP, CA 19-9, neuroendocrine markers and routine bloods; tumour-board planning; genetic counselling; nutrition and pancreatic enzyme support; pain relief, psycho-oncology and supportive care; and long-term follow-up. Pancreatic cancer treatment in Hyderabad sets out how those services run across the network.

Coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres, and may be billed there: all pancreatic surgery, from removing a small hormone-producing tumour to the larger resections; endoscopic ultrasound with biopsy; ERCP and biliary or duodenal stenting; staging laparoscopy; coeliac plexus block for pain; PET-CT and DOTATATE PET; and peptide receptor radionuclide therapy. We arrange these, we sit in on the decisions and we tell you in advance where each one happens and who invoices you. We do not describe them as our own theatre, endoscopy or radionuclide lists, because they are not.

The most common harm this confusion does is not medical, it is informational. Someone with a neuroendocrine tumour reads figures that describe ductal adenocarcinoma, concludes the situation is far worse than it is, and spends weeks inside a fear that does not belong to them. It happens often, and it is avoidable. The mirror image is just as damaging: someone with an adenocarcinoma who has been told loosely that theirs is “a slow-growing type” can lose the short window in which treatment decisions matter most.

So be direct with the team. Ask which of the two you have, ask for it in writing, and ask which figures apply. Where a survival number is quoted at you, ask what group it was drawn from, when that group was treated, and whether it mixed the two diseases together. Pooled pancreatic series often do exactly that, which drags the neuroendocrine picture down for no good reason and flatters the ductal one. PNET prognosis and survival explains what genuinely shifts the outlook on the neuroendocrine side, without pretending that a group average describes one person.

None of this makes either diagnosis easier to receive. A well-differentiated PNET is still a cancer that needs a plan and long follow-up, and a ductal adenocarcinoma found early and cleanly removable can be cured. The point of separating them is neither optimism nor pessimism — it is that the right label puts you in front of the right tests, the right treatment and the right numbers. The complete pancreatic cancer guide covers the wider picture, and pancreatic ductal adenocarcinoma explained goes deeper into the common type.

Medical disclaimer: This page compares pancreatic neuroendocrine tumours with pancreatic ductal adenocarcinoma and is reviewed by a CION medical oncologist with reference to NCCN guidance on neuroendocrine tumours and on pancreatic adenocarcinoma. It is general information; which diagnosis applies to you is established by your own pathology and imaging and must be confirmed with your treating team, and no survival figure is stated here because no published figure describes an individual. Chemotherapy and other systemic therapy, radiation, chemoradiation and SBRT, ordering and reporting of pancreatic-protocol CT, MRI/MRCP, CA 19-9, neuroendocrine markers and bloods, tumour-board planning, genetic counselling, nutrition and pancreatic enzyme (PERT) support, pain relief, psycho-oncology and survivorship care are delivered by CION; all pancreatic surgery, endoscopic ultrasound and biopsy, ERCP and biliary or duodenal stenting, staging laparoscopy, coeliac plexus block, PET-CT and DOTATATE PET, and peptide receptor radionuclide therapy are coordinated with specialist hepatobiliary, gastroenterology, endoscopy and nuclear medicine partner centres and may be billed there.